Guangzhou Innogen Pharmaceutical Group Co Ltd (HKSE:02591) Share Price

Company Profile

Business description
Guangzhou Innogen Pharmaceutical Group Co Ltd is a company in Asia to commercialize an innovative, humanized, long-acting glucagon-like peptide-1 (GLP-1) receptor agonist. It has commercialized Efsubaglutide Alfa (brand name: Diabegone), its Core Product, for the treatment of type 2 diabetes (T2D) in China. Its core business model is to discover, develop and commercialize innovative therapies for diabetes and other metabolic diseases. The company has built a pipeline of drug candidates targeting diabetes and other metabolic diseases.
Contact
No. 2 Tengfei Second Street
Room 409, Building H Self-numbered Creative Building
China-Singapore Guangzhou Knowledge City
Huangpu District, Guangdong Province
Guangzhou
CHN
https://www.innogenpharm.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
96

Recommended

Stronger-than-expected AI demand internationally and domestically.

Chelsey Tam | 28 September 2025

Downgrading our estimates due to lower growth.

Mark Taylor | 28 September 2025

Undervalued by 23%, this cheap dividend stock is a top pick in its sector.

Travis Miller | 28 September 2025

Index	Last price	Change	% Change
All Ordinaries	9,148.50	45.40	0.50%
CAC 40	7,890.85	20.17	0.26%
DAX 40	23,790.50	51.03	0.21%
Dow JONES (US)	46,247.29	299.97	0.65%
FTSE 100	9,329.36	44.53	0.48%
HKSE	26,622.88	494.68	1.89%
NASDAQ	22,484.07	99.37	0.44%
Nikkei 225	45,043.75	311.24	-0.69%
NZX 50 Index	13,132.56	20.83	0.16%
S&P 500	6,643.70	38.98	0.59%
S&P/ASX 200	8,862.80	52.10	0.59%
SSE Composite Index	3,862.53	34.43	0.90%